INT268903

Context Info Confidence 0.75 First Reported 2007 Last Reported 2008 Negated 0 Speculated 0 Reported most in Body Documents 5 Total Number 5 Disease Relevance 0.83 Pain Relevance 0.20

enzyme regulator activity (Sln)

Anatomy Link Frequency blood 1 Sln (Rattus norvegicus)

Pain Link Frequency Relevance Heat Bioavailability 12 94.68 Neuritis 1 84.08 Pain 4 5.00 imagery 4 5.00

Disease Link Frequency Relevance Heat Renal Failure 1 87.44 Optic Neuritis 1 84.56 Blindness 1 82.56 Nephrotoxicity 1 82.20 Necrosis 1 79.92 Encephalopathy 1 78.64 Cardiovascular Disorder Under Development 1 77.12 Toxicity 5 75.92 Cancer 2 55.08 Diabetes Mellitus 24 5.00

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

This knowledge can be used to adjust degradation of SLN and consequently drug release in a controlled way (Olbrich and Muller 1999).

Protein_catabolism (degradation) of SLN

1) Confidence 0.75 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0.08 Pain Relevance 0.03

The longer the ethylene oxide chains are in the molecule, the more hindered is the anchoring of the lipase/co-lipase complex and consequently the degradation of the SLN.

Protein_catabolism (degradation) of SLN

2) Confidence 0.65 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0.07 Pain Relevance 0.03

SLN show different degradation rates by the lipolytic enzyme pancreatic lipase as a function of their composition (lipid matrix, stabilizing surfactant) and it has been demonstrated that the longer the fatty acid chains of the acylglycerols are, the slower is their degradation (Olbrich and Muller 1999).

Protein_catabolism (degradation) of SLN

3) Confidence 0.65 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0 Pain Relevance 0.05

The additional advantage of the SLN are the large scale production, protection of the drug against chemical degradation, ease of modulation of the drug release profile and high drug pay load3.

Protein_catabolism (degradation) of SLN

4) Confidence 0.59 Published 2008 Journal Indian Journal of Pharmaceutical Sciences Section Body Doc Link PMC2792476 Disease Relevance 0.68 Pain Relevance 0.08

Afterwards, it can be postulated that SLN undergo physiological degradation and the insulin enter into the blood circulation.

Protein_catabolism (degradation) of SLN in blood

5) Confidence 0.58 Published 2007 Journal International Journal of Nanomedicine Section Body Doc Link PMC2676823 Disease Relevance 0 Pain Relevance 0

General Comments

This test has worked.